Tag: BRCA1BRCA2

Articles

• BRCA1 and BRCA2 mutation carriers
• Breast cancer in very young women
• Foods to eat and avoid for BRCA1 and BRCA2 carriers
• Latinas less likely to develop BC but outcomes are less favorable
• Male breast cancer risk, treatment and prognosis
• Protecting our daughters from BC — Prenatal period & infancy
• Protecting our sons from breast cancer
• Triple negative breast cancer characteristics
• Young breast cancer survivors can reduce risk of recurrence

News

09/10/21

Dietary polyphenols can counteract harmful BRCA mutations

03/25/13

Non-BRCA carriers in BRCA families may get BC at younger age

01/10/12

Father's breast cancer or BRCA mutation influences daughter's risk

11/11/11

Nigerian breast cancer patients have high rates of BRCA mutations

10/18/11

Previous appendectomy linked to cancer in Jewish BRCA carriers

10/10/11

BRCA carriers are diagnosed earlier than previous generation

06/26/11

Women inheriting BRCA mutations from fathers get BC at a younger age

09/14/10

Does a family history of BC increase the risk of certain subtypes?

03/10/10

Breast tissue of high risk women resembles nontumor tissue of patients

Studies

• Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study Cite
  Cortés-Salgado A, Serrano JJ, Cordero Pereda D, Menacho M, Del Rey JM, del Campo-Albendea L, et al. Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study. The Oncologist. Oxford University Press (OUP); 2024; 10.1093/oncolo/oyae299
• Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers Cite
  Allen I, Hassan H, Walburga Y, Huntley C, Loong L, Rahman T, et al. Second Primary Cancer Risks After Breast Cancer in BRCA1 and BRCA2 Pathogenic Variant Carriers. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 10.1200/jco.24.01146
• Disparities in Hereditary Genetic Testing in Patients with Triple Negative Breast Cancer Cite
  Gupta S, Jones JE, Smith-Graziani D. Disparities in Hereditary Genetic Testing in Patients with Triple Negative Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2024; 10.1016/j.clbc.2024.09.018
• Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2 Cite
  Phillips K, Kotsopoulos J, Domchek SM, Terry MB, Chamberlain JA, Bassett JK, et al. Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2024; 10.1200/jco.24.00176
• Factors influencing prophylactic surgical intervention in women with genetic predisposition for breast cancer Cite
  Humar P, Balogun Z, Douglas N, Glenney A, Kass NM, Moroni EA, et al. Factors influencing prophylactic surgical intervention in women with genetic predisposition for breast cancer. Journal of Surgical Oncology. Wiley; 2024; 10.1002/jso.27817
• Incidence of endometrial cancer in BRCA mutation carriers Cite
  Kotsopoulos J, Lubinski J, Huzarski T, Bychkovsky BL, Moller P, Kim RH, et al. Incidence of endometrial cancer in BRCA mutation carriers. Gynecologic Oncology. Elsevier BV; 2024; 189:148-155 10.1016/j.ygyno.2024.07.687
• BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients Cite
  Cheng HH, Shevach JW, Castro E, Couch FJ, Domchek SM, Eeles RA, et al. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients. JAMA Oncology. American Medical Association (AMA); 2024; 10.1001/jamaoncol.2024.2185
• Can contralateral prophylactic mastectomy and oophorectomy increase survival in BRCA-related breast cancer? Results from the Italian MUTina study Cite
  Cortesi L, Cortesi G, Venturelli M, Marcheselli L, Toss A, Barbieri E, et al. Can contralateral prophylactic mastectomy and oophorectomy increase survival in BRCA-related breast cancer? Results from the Italian MUTina study. European Journal of Surgical Oncology. Elsevier BV; 2024;:108603 10.1016/j.ejso.2024.108603
• BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients Cite
  Cheng HH, Shevach JW, Castro E, Couch FJ, Domchek SM, Eeles RA, et al. BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients. JAMA Oncology. American Medical Association (AMA); 2024; 10.1001/jamaoncol.2024.2185
• Antioxidant Properties of Zinc and Copper—Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers Cite
  Matuszczak M, Kiljańczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P, et al. Antioxidant Properties of Zinc and Copper—Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation Carriers. Antioxidants. MDPI AG; 2024; 13:841 10.3390/antiox13070841
• Single crystal XRD analysis, Molecular docking, DFT studies, Hirshfeld analysis, antioxidant and anticancer activities of three natural carboxylic acids identified in Carica papaya leaves Cite
  Maruthanila V, Elancheran R, Chandraboss V, Kabilan S, Mirunalini S. Single crystal XRD analysis, Molecular docking, DFT studies, Hirshfeld analysis, antioxidant and anticancer activities of three natural carboxylic acids identified in Carica papaya leaves. Journal of Molecular Structure. Elsevier BV; 2024;:139131 10.1016/j.molstruc.2024.139131
• BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants? Cite
  Fanale D, Corsini LR, Brando C, Randazzo U, Bono M, Pedone E, et al. BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants?. Frontiers in Oncology. Frontiers Media SA; 2024; 14 10.3389/fonc.2024.1414343
• Participation in a High-Risk Program Is Associated with a Diagnosis of Earlier-Stage Disease Among Women at Increased Risk for Breast Cancer Development Cite
  Pilewskie M, Eroglu I, Sevilimedu V, Le T, Mangino D, Morrow M. Participation in a High-Risk Program Is Associated with a Diagnosis of Earlier-Stage Disease Among Women at Increased Risk for Breast Cancer Development. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-15633-x
• Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy Cite
  Gootzen T, Steenbeek M, van Bommel M, IntHout J, Kets C, Hermens R, et al. Risk-reducing salpingectomy with delayed oophorectomy to prevent ovarian cancer in women with an increased inherited risk: insights into an alternative strategy. Familial Cancer. Springer Science and Business Media LLC; 2024; 10.1007/s10689-024-00412-0
• Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants Cite
  Wen S, Zhang M, Chen J, Hu L, Sun J, Yao L, et al. Characteristics of Chinese breast cancer patients with double heterozygosity for BRCA1 and BRCA2 germline pathogenic variants. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07409-4
• Cost-effectiveness of BRCA1 testing at time of obstetrical prenatal carrier screening for cancer prevention Cite
  Dioun SM, Perez LR, Prabhu M, Brewer JT, Ahsan MD, Hou JY, et al. Cost-effectiveness of BRCA1 testing at time of obstetrical prenatal carrier screening for cancer prevention. American Journal of Obstetrics and Gynecology. Elsevier BV; 2024; 10.1016/j.ajog.2024.04.014
• Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers Cite
  Matuszczak M, Kiljańczyk A, Marciniak W, Derkacz R, Stempa K, Baszuk P, et al. Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation Carriers. Antioxidants. MDPI AG; 2024; 13:609 10.3390/antiox13050609
• Pathogenic BRCA Variants in the Ashkenazi Jewish Population: A Retrospective Study [ID 2683559] Cite
  Barkan S, Kuizon CM, Ruiz-Pelaez JG, Etkin-Kramer E. Pathogenic BRCA Variants in the Ashkenazi Jewish Population: A Retrospective Study [ID 2683559]. Obstetrics & Gynecology. Ovid Technologies (Wolters Kluwer Health); 2024; 143:73S-73S 10.1097/01.aog.0001013960.08426.ef
• Methyl CpG binding protein MBD2 has a regulatory role on the BRCA1 gene expression and its modulation by resveratrol in ER+, PR+ & triple-negative breast cancer cells Cite
  Sahu RK, Tandon S, Singh S, Das BC, Hedau ST. Methyl CpG binding protein MBD2 has a regulatory role on the BRCA1 gene expression and its modulation by resveratrol in ER+, PR+ & triple-negative breast cancer cells. BMC Cancer. Springer Science and Business Media LLC; 2024; 24 10.1186/s12885-024-12274-x
• Abstract PS10-01: Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Pathogenic Variants in BRCA1 and BRCA2 Cite
  Phillips K, Kotsopoulos J, Domchek S, Chamberlain J, Bassett J, Aeilts A, et al. Abstract PS10-01: Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Pathogenic Variants in BRCA1 and BRCA2. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PS10-01-PS10-01 10.1158/1538-7445.sabcs23-ps10-01
• Abstract PO1-16-10: BRCA mutated Male Breast Cancer, hallmarks of a distinct disease. Data from the Spanish Male Breast Cancer Registry (GEICAM/2016-04) Cite
  Martínez-Jáñez N, Martínez P, Hernando C, Recalde S, Sánchez A, Morales D, et al. Abstract PO1-16-10: BRCA mutated Male Breast Cancer, hallmarks of a distinct disease. Data from the Spanish Male Breast Cancer Registry (GEICAM/2016-04). Cancer Research. American Association for Cancer Research (AACR); 2024; 84:PO1-16-10-PO1-16-10 10.1158/1538-7445.sabcs23-po1-16-10
• Second Primary Breast Cancer in Young Breast Cancer Survivors Cite
  Brantley KD, Rosenberg SM, Collins LC, Ruddy KJ, Tamimi RM, Schapira L, et al. Second Primary Breast Cancer in Young Breast Cancer Survivors. JAMA Oncology. American Medical Association (AMA); 2024; 10.1001/jamaoncol.2024.0286
• Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study Cite
  Pla-Juher H, Pardo M, Izquierdo ÀJ, Darder E, Carbó A, Munté E, et al. Risk of endometrial cancer after RRSO in BRCA 1/2 carriers: a multicentre cohort study. Clinical and Translational Oncology. Springer Science and Business Media LLC; 2023; 26:1033-1037 10.1007/s12094-023-03312-4
• Abstract 7321: Second primary cancer risks following breast cancer in BRCA1/2 pathogenic variant carriers Cite
  Allen I, Hassan H, Walburga Y, Huntley C, Loong L, Rahman T, et al. Abstract 7321: Second primary cancer risks following breast cancer in BRCA1/2 pathogenic variant carriers. Cancer Research. American Association for Cancer Research (AACR); 2024; 84:7321-7321 10.1158/1538-7445.am2024-7321
• Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations Cite
  Kotsopoulos J, Gronwald J, Huzarski T, Møller P, Pal T, McCuaig JM, et al. Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. American Medical Association (AMA); 2024; 10.1001/jamaoncol.2023.6937
• Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer Cite
  Xiao Q, Mao X, Ploner A, Grassmann F, Rodriguez J, Eriksson M, et al. Cancer risks among first-degree relatives of women with a genetic predisposition to breast cancer. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2024; 10.1093/jnci/djae030
• The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy Cite
  Mutai R, Kuchuk I, Goldshtein A, Yerushalmi R, Rotem O, Maisel Lotan A, et al. The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 10.1007/s10549-024-07247-4
• BRCA1 protein dose-dependent risk for embryonic oxidative DNA damage, embryopathies and neurodevelopmental disorders with and without ethanol exposure Cite
  Drake DM, Afsharian K, Or B, Shapiro AM, Lai ML, Miller L, et al. BRCA1 protein dose-dependent risk for embryonic oxidative DNA damage, embryopathies and neurodevelopmental disorders with and without ethanol exposure. Redox Biology. Elsevier BV; 2024;:103070 10.1016/j.redox.2024.103070
• Exploring Citrus sinensis Phytochemicals as Potential Inhibitors for Breast Cancer Genes BRCA1 and BRCA2 Using Pharmacophore Modeling, Molecular Docking, MD Simulations, and DFT Analysis Cite
  Zia M, Parveen S, Shafiq N, Rashid M, Farooq A, Dauelbait M, et al. Exploring Citrus sinensis Phytochemicals as Potential Inhibitors for Breast Cancer Genes BRCA1 and BRCA2 Using Pharmacophore Modeling, Molecular Docking, MD Simulations, and DFT Analysis. ACS Omega. American Chemical Society (ACS); 2024; 10.1021/acsomega.3c05098
• Survival outcomes of patients with HER2/neu‐positive breast cancer with germline BRCA mutations Cite
  Akkoc Mustafayev FN, Shukla MA, Lanier A, Milton DR, Gutierrez AM, Gruschkus SK, et al. Survival outcomes of patients with HER2/neu‐positive breast cancer with germline BRCA mutations. Cancer. Wiley; 2023; 10.1002/cncr.35159
• Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients Cite
  Vidarsdottir L, Olafsdottir EJ, Barkardottir RB, Bjarnadottir O, Jonasson JG, Sigurdsson S, et al. Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients. npj Breast Cancer. Springer Science and Business Media LLC; 2023; 9 10.1038/s41523-023-00600-8
• Pregnancy After Breast Cancer in Young BRCA Carriers Cite
  Lambertini M, Blondeaux E, Agostinetto E, Hamy A, Kim HJ, Di Meglio A, et al. Pregnancy After Breast Cancer in Young BRCA Carriers. JAMA. American Medical Association (AMA); 2023; 10.1001/jama.2023.25463
• Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis Cite
  Metcalfe K, Huzarski T, Gronwald J, Kotsopoulos J, Kim R, Moller P, et al. Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis. British Journal of Cancer. Springer Science and Business Media LLC; 2023; 10.1038/s41416-023-02503-8
• Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer Cite
  Myers SP, Sevilimedu V, Barrio AV, Tadros AB, Mamtani A, Robson ME, et al. Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14319-0
• SAT428 The Effects Of Diphenyl Phthalate (DP) On Estrogen Receptor Alpha (ERα;) And Tumor Suppressor Gene (BRCA-1) In Breast Cancer Cells Cite
  Whittaker K, Hallman E, Zanib A, Pfiffner S, Yaldo R, Dinda S. SAT428 The Effects Of Diphenyl Phthalate (DP) On Estrogen Receptor Alpha (ERα;) And Tumor Suppressor Gene (BRCA-1) In Breast Cancer Cells. Journal of the Endocrine Society. The Endocrine Society; 2023; 7 10.1210/jendso/bvad114.1059
• Breast Cancer Genes and Contralateral Prophylactic Mastectomy: Beyond BRCA Cite
  Tuttle TM, Hui JYC. Breast Cancer Genes and Contralateral Prophylactic Mastectomy: Beyond BRCA. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14161-4
• Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer Cite
  Öfverholm A, Törngren T, Rosén A, Arver B, Einbeigi Z, Haraldsson K, et al. Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer. BMC Cancer. Springer Science and Business Media LLC; 2023; 23 10.1186/s12885-023-11229-y
• Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: different biological and clinical entities with potentially diverse therapeutic opportunities Cite
  Zattarin E, Taglialatela I, Lobefaro R, Leporati R, Fucà G, Ligorio F, et al. Breast cancers arising in subjects with germline BRCA1 or BRCA2 mutations: different biological and clinical entities with potentially diverse therapeutic opportunities. Critical Reviews in Oncology/Hematology. Elsevier BV; 2023;:104109 10.1016/j.critrevonc.2023.104109
• Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients? Cite
  Lee MK, Robson ME. Contralateral breast cancer risk with radiation therapy in BRCA mutation carriers: what do we tell patients?. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2023; 10.1093/jnci/djad129
• Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation Cite
  Tuna M, Özgen L, Yalcin Y, Ozerkan K. Clinical significance of risk-reducing salpingo-oophorectomy in patients with BRCA1/2 mutation. Journal of Gynecology Obstetrics and Human Reproduction. Elsevier BV; 2023;:102642 10.1016/j.jogoh.2023.102642
• Risk Factors for Developing Both Primary Breast and Primary Ovarian Cancer: A Systematic Review Cite
  Ferris JS, Morgan DA, Tseng AS, Terry MB, Ottman R, Hur C, et al. Risk Factors for Developing Both Primary Breast and Primary Ovarian Cancer: A Systematic Review. Critical Reviews in Oncology/Hematology. Elsevier BV; 2023;:104081 10.1016/j.critrevonc.2023.104081
• BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance Cite
  Shu X, Li J, Chan UI, Su SM, Shi C, Zhang X, et al. BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:2614-2633 10.1158/0008-5472.can-22-3398
• Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation Cite
  Kotsopoulos J, Gronwald J, Huzarski T, Aeilts A, Randall Armel S, Karlan B, et al. Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-06991-3
• Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium Cite
  Kast K, John EM, Hopper JL, Andrieu N, Noguès C, Mouret-Fourme E, et al. Associations of height, body mass index, and weight gain with breast cancer risk in carriers of a pathogenic variant in BRCA1 or BRCA2: the BRCA1 and BRCA2 Cohort Consortium. Breast Cancer Research. Springer Science and Business Media LLC; 2023; 25 10.1186/s13058-023-01673-w
• Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study Cite
  Bucalo A, Conti G, Valentini V, Capalbo C, Bruselles A, Tartaglia M, et al. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study. European Journal of Cancer. Elsevier BV; 2023; 188:183-191 10.1016/j.ejca.2023.04.022
• 181P Male breast cancer (MBC): Familial history (FH), clinicopathological (CP) characteristics, oncogenetic (OG) testing and outcome in a cohort of 98 patients (pts) Cite
  Chretien S, Aymes E, Barthoulot M, Deley ML, Boulaire M, Oca F, et al. 181P Male breast cancer (MBC): Familial history (FH), clinicopathological (CP) characteristics, oncogenetic (OG) testing and outcome in a cohort of 98 patients (pts). ESMO Open. Elsevier BV; 2023; 8:101458 10.1016/j.esmoop.2023.101458
• The association between age at breast cancer diagnosis and prevalence of pathogenic variants Cite
  Daly MB, Rosenthal E, Cummings S, Bernhisel R, Kidd J, Hughes E, et al. The association between age at breast cancer diagnosis and prevalence of pathogenic variants. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 199:617-626 10.1007/s10549-023-06946-8
• Abstract 988: Long-term health outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer Cite
  Hassan H, Rahman T, Bacon A, Knott C, Allen I, Huntley C, et al. Abstract 988: Long-term health outcomes of bilateral salpingo-oophorectomy in women with personal history of breast cancer. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:988-988 10.1158/1538-7445.am2023-988
• Association of Premenopausal Bilateral Oophorectomy With Parkinsonism and Parkinson Disease Cite
  Rocca WA, Smith CY, Gazzuola Rocca L, Savica R, Mielke MM. Association of Premenopausal Bilateral Oophorectomy With Parkinsonism and Parkinson Disease. JAMA Network Open. American Medical Association (AMA); 2022; 5:e2238663 10.1001/jamanetworkopen.2022.38663
• Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience Cite
  Nagashima M, Ishikawa T, Asami Y, Hirose Y, Shimada K, Miyagami S, et al. Risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer: a single-institution 10-year experience. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2023; 10.1093/jjco/hyad020
• Discovery of Potential Phytochemicals from Carica papaya Targeting BRCA-1 in Breast Cancer Treatment Cite
  Ibrahim A, Ipinloju N, Aiyelabegan AO, Alfa-Ibrahim AA, Muhammad SA, Oyeneyin OE. Discovery of Potential Phytochemicals from Carica papaya Targeting BRCA-1 in Breast Cancer Treatment. Applied Biochemistry and Biotechnology. Springer Science and Business Media LLC; 2023; 10.1007/s12010-023-04473-2
• Molecular characteristics of Asian male BRCA-related cancers Cite
  Kwong A, Ho CYS, Shin VY, Ng ATL, Chan TL, Ma ESK. Molecular characteristics of Asian male BRCA-related cancers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 198:391-400 10.1007/s10549-022-06651-y
• Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2 Cite
  Bhardwaj P, Iyengar NM, Zahid H, Carter KM, Byun DJ, Choi MH, et al. Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2. Science Translational Medicine. American Association for the Advancement of Science (AAAS); 2023; 15 10.1126/scitranslmed.ade1857
• Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis Cite
  Gaba F, Blyuss O, Tan A, Munblit D, Oxley S, Khan K, et al. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in BRCA Carriers: A Systematic Review and Meta-Analysis. Cancers. MDPI AG; 2023; 15:1625 10.3390/cancers15051625
• Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants Cite
  Liu X, Wang Y, Cao K, Yao L, Hu L, Sun J, et al. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-06904-4
• Abstract P1-09-11: Impact of breast surgical procedure on survival in BRCA mutated patients with invasive breast cancer: mastectomy versus conservative treatment Cite
  JANKOWSKI C, Mahiou K, Laura V, Costaz H, padéano M, Causeret S, et al. Abstract P1-09-11: Impact of breast surgical procedure on survival in BRCA mutated patients with invasive breast cancer: mastectomy versus conservative treatment. Cancer Research. American Association for Cancer Research (AACR); 2023; 83:P1-09-11-P1-09-11 10.1158/1538-7445.sabcs22-p1-09-11
• The risks of cancer in older women with BRCA pathogenic variants: How far have we come? Cite
  Metcalfe KA, Gronwald J, Tung NM, McCuaig JM, Eisen A, Elser C, et al. The risks of cancer in older women with BRCA pathogenic variants: How far have we come?. Cancer. Wiley; 2022; 129:901-907 10.1002/cncr.34615
• Prognostic and Predictive Biomarkers in Familial Breast Cancer Cite
  Deb S, Chakrabarti A, Fox SB. Prognostic and Predictive Biomarkers in Familial Breast Cancer. Cancers. MDPI AG; 2023; 15:1346 10.3390/cancers15041346
• Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review Cite
  Bertozzi S, Londero AP, Xholli A, Azioni G, Di Vora R, Paudice M, et al. Risk-Reducing Breast and Gynecological Surgery for BRCA Mutation Carriers: A Narrative Review. Journal of Clinical Medicine. MDPI AG; 2023; 12:1422 10.3390/jcm12041422
• The Role of Cow’s Milk Consumption in Breast Cancer Initiation and Progression Cite
  Melnik BC, John SM, Carrera-Bastos P, Cordain L, Leitzmann C, Weiskirchen R, et al. The Role of Cow’s Milk Consumption in Breast Cancer Initiation and Progression. Current Nutrition Reports. Springer Science and Business Media LLC; 2023; 10.1007/s13668-023-00457-0
• Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Noncarriers Cite
  Lewinsohn R, Zheng Y, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, et al. Fertility Preferences and Practices Among Young Women With Breast Cancer: Germline Genetic Carriers Versus Noncarriers. Clinical Breast Cancer. Elsevier BV; 2022; 10.1016/j.clbc.2022.12.012
• Interactions dietary components with expression level of breast cancer-related genes Cite
  Bourbour F, Pourtaheri A, Abbasi K, Hasanpour Ardekanizadeh N, Gholamalizadeh M, Hajipour A, et al. Interactions dietary components with expression level of breast cancer-related genes. Egyptian Journal of Medical Human Genetics. Springer Science and Business Media LLC; 2022; 23 10.1186/s43042-022-00375-w
• Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer Cite
  Shimomura A, Yoshida M, Kubo T, Yamashita S, Noguchi E, Nagayama A, et al. Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06822-x
• BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy Cite
  Choi E, Mun G, Lee J, Lee H, Cho J, Lee Y. BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy. Biomedicine & Pharmacotherapy. Elsevier BV; 2023; 158:114090 10.1016/j.biopha.2022.114090
• Genetic Predisposition to Male Breast Cancer: A Case Series Cite
  APESSOS A, AGIANNITOPOULOS K, PEPE G, TSAOUSIS GN, PITTA P, BILI C, et al. Genetic Predisposition to Male Breast Cancer: A Case Series. Anticancer Research. Anticancer Research USA Inc.; 2022; 42:5795-5801 10.21873/anticanres.16086
• Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis Cite
  van Bommel MHD, IntHout J, Veldmate G, Kets CM, de Hullu JA, van Altena AM, et al. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis. Human Reproduction Update. Oxford University Press (OUP); 2022; 10.1093/humupd/dmac038
• Longitudinal Serum Protein Analysis of Women with a High Risk of Developing Breast Cancer Reveals Large Interpatient Versus Small Intrapatient Variations: First Results from the TESTBREAST Study Cite
  Hagenaars SC, Dekker LJM, Ravesteijn B, van Vlierberghe RLP, Romijn FPHTM, Verhoeff L, et al. Longitudinal Serum Protein Analysis of Women with a High Risk of Developing Breast Cancer Reveals Large Interpatient Versus Small Intrapatient Variations: First Results from the TESTBREAST Study. International Journal of Molecular Sciences. MDPI AG; 2022; 23:12399 10.3390/ijms232012399
• High risk breast cancer screening is a double edged sword: A qualitative study of patient perspectives on the Ontario High Risk Breast Cancer Screening Program Cite
  Deng SX, Castelo M, Reel E, Naganathan G, Eisen A, Muradali D, et al. High risk breast cancer screening is a double edged sword: A qualitative study of patient perspectives on the Ontario High Risk Breast Cancer Screening Program. Clinical Breast Cancer. Elsevier BV; 2022; 10.1016/j.clbc.2022.08.004
• Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers Cite
  Nemati Shafaee M, Goutsouliak K, Lin H, Bevers TB, Gutierrez-Barrera A, Bondy M, et al. Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06688-z
• Surgical management of BRCA-mutation carriers: A single institution experience Cite
  Gentile D, Losurdo A, Sagona A, Zuradelli M, Gatzemeier W, Barbieri E, et al. Surgical management of BRCA-mutation carriers: A single institution experience. European Journal of Surgical Oncology. Elsevier BV; 2022; 48:1706-1712 10.1016/j.ejso.2022.04.024
• Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer Cite
  Viansone A, Pellegrino B, Omarini C, Pistelli M, Boggiani D, Sikokis A, et al. Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer. The Breast. Elsevier BV; 2022; 65:145-150 10.1016/j.breast.2022.07.012
• Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study Cite
  Chen F, Park SL, Wilkens LR, Wan P, Hart SN, Hu C, et al. Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study. Cancer Research. American Association for Cancer Research (AACR); 2022; 10.1158/0008-5472.can-21-4461
• Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis Cite
  Tomasello G, Gambini D, Petrelli F, Azzollini J, Arcanà C, Ghidini M, et al. Characterization of the HER2 status in BRCA-mutated breast cancer: a single institutional series and systematic review with pooled analysis. ESMO Open. Elsevier BV; 2022; 7:100531 10.1016/j.esmoop.2022.100531
• Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal Cite
  Kotsopoulos J, Lubinski J, Gronwald J, Menkiszak J, McCuaig J, Metcalfe K, et al. Bilateral Oophorectomy and the Risk of Breast Cancer in BRCA1 Mutation Carriers: A Reappraisal. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2022; 31:1351-1358 10.1158/1055-9965.epi-21-1196
• Machine learning-based screening of MCF-7 human breast cancer cells and molecular docking analysis of essential oils from Ocimum basilicum against breast cancer Cite
  Nguyen TK, Nguyen TNL, Nguyen K, Nguyen HVT, Tran LTT, Ngo TXT, et al. Machine learning-based screening of MCF-7 human breast cancer cells and molecular docking analysis of essential oils from Ocimum basilicum against breast cancer. Journal of Molecular Structure. Elsevier BV; 2022; 1268:133627 10.1016/j.molstruc.2022.133627
• Physical Activity in Young BRCA Carriers and Reduced Risk of Breast Cancer Cite
  Bucy AM, Valencia CI, Howe CL, Larkin TJ, Conard KD, Anderlik EW, et al. Physical Activity in Young BRCA Carriers and Reduced Risk of Breast Cancer. American Journal of Preventive Medicine. Elsevier BV; 2022; 10.1016/j.amepre.2022.04.022
• Fertility Considerations for Reproductive-Aged Carriers of Deleterious BRCA Mutations: A Call for Early Intervention Cite
  Fine E, Knoll MA, Maslow BL. Fertility Considerations for Reproductive-Aged Carriers of Deleterious BRCA Mutations: A Call for Early Intervention. JCO Oncology Practice. American Society of Clinical Oncology (ASCO); 2022; 18:165-168 10.1200/op.21.00389
• Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland Cite
  Pallonen TA, Lempiäinen SMM, Joutsiniemi TK, Aaltonen RI, Pohjola PE, Kankuri-Tammilehto MK. Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-022-10519-y
• BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis Cite
  Nyberg T, Tischkowitz M, Antoniou AC. BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 126:1067-1081 10.1038/s41416-021-01675-5
• Abstract P3-12-25: Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study Cite
  Kim H, Kim SS, Lee JS, Yoon JS, Shin HJ, Lee JE, et al. Abstract P3-12-25: Risk of second primary cancers after curative treatment of breast cancer: A Korean nationwide population-based study. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P3-12-25-P3-12-25 10.1158/1538-7445.sabcs21-p3-12-25
• Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study Cite
  de Jonge MM, de Kroon CD, Jenner DJ, Oosting J, de Hullu JA, Mourits MJE, et al. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 113:1203-1211 10.1093/jnci/djab036
• Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores Cite
  Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, et al. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 114:109-122 10.1093/jnci/djab147
• Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. Cite
  Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJ, Andrieu N, et al. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. Apollo - University of Cambridge Repository; 2022; 10.17863/CAM.80147
• Bilateral Salpingo-oophorectomy and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Assessing the Evidence Cite
  Conduit C, Milne RL, Friedlander ML, Phillips K. Bilateral Salpingo-oophorectomy and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Assessing the Evidence. Cancer Prevention Research. American Association for Cancer Research (AACR); 2021; 14:983-994 10.1158/1940-6207.capr-21-0141
• Predictive and prognostic significance of BRCAness in HER2-negative breast cancer Cite
  Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, et al. Predictive and prognostic significance of BRCAness in HER2-negative breast cancer. Breast Cancer. Springer Science and Business Media LLC; 2022; 10.1007/s12282-021-01319-9
• Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: A meta-analysis of observational studies Cite
  Park J, Huang D, Chang YJ, Lim MC, Myung S. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: A meta-analysis of observational studies. Carcinogenesis. Oxford University Press (OUP); 2021; 10.1093/carcin/bgab107
• Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing Cite
  Southey MC, Dowty JG, Riaz M, Steen JA, Renault A, Tucker K, et al. Population-based estimates of breast cancer risk for carriers of pathogenic variants identified by gene-panel testing. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00360-3
• Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort Cite
  Bruno E, Oliverio A, Paradiso A, Daniele A, Tommasi S, Terribile DA, et al. Lifestyle Characteristics in Women Carriers of BRCA Mutations: Results From an Italian Trial Cohort. Clinical Breast Cancer. Elsevier BV; 2021; 21:e168-e176 10.1016/j.clbc.2020.11.002
• Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer Cite
  Nañez A, Stram DA, Bethan Powell C, Garcia C. Breast cancer risk in BRCA mutation carriers after diagnosis of epithelial ovarian cancer is lower than in carriers without ovarian cancer. Gynecologic Oncology Reports. Elsevier BV; 2022; 39:100899 10.1016/j.gore.2021.100899
• Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? A Mini review Cite
  Daniele A, Divella R, Pilato B, Tommasi S, Pasanisi P, Patruno M, et al. Can harmful lifestyle, obesity and weight changes increase the risk of breast cancer in BRCA 1 and BRCA 2 mutation carriers? A Mini review. Hereditary Cancer in Clinical Practice. Springer Science and Business Media LLC; 2021; 19 10.1186/s13053-021-00199-6
• Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists Cite
  Ademuyiwa FO, Salyer P, Tao Y, Luo J, Hensing WL, Afolalu A, et al. Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021; 10.1200/jco.21.01426
• Care of men with cancer-predisposing BRCA variants Cite
  Horton R, Pharoah P, Hayward J, Lucassen A. Care of men with cancer-predisposing BRCA variants. BMJ. BMJ; 2021;:n2376 10.1136/bmj.n2376
• Penetrance of male breast cancer susceptibility genes: a systematic review Cite
  Chamseddine RS, Wang C, Yin K, Wang J, Singh P, Zhou J, et al. Penetrance of male breast cancer susceptibility genes: a systematic review. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06413-2
• Modulation of interaction of BRCA1-RAD51 and BRCA1-AURKA protein complexes by natural metabolites using as possible therapeutic intervention toward cardiotoxic effects of cancer drugs: an in-silico approach Cite
  Tiwari S, Pandey VP, Yadav K, Dwivedi UN. Modulation of interaction of BRCA1-RAD51 and BRCA1-AURKA protein complexes by natural metabolites using as possible therapeutic intervention toward cardiotoxic effects of cancer drugs: an in-silico approach. Journal of Biomolecular Structure and Dynamics. Informa UK Limited; 2021;:1-17 10.1080/07391102.2021.1976278
• How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers? Cite
  Garstka M, Henriquez A, Kelly BN, Webster A, Khubchandani JA, Hughes K, et al. How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 28:5657-5662 10.1245/s10434-021-10445-9
• Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study Cite
  Koh S, Ohsumi S, Takahashi M, Fukuma E, Jung KH, Ishida T, et al. Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Breast Cancer. Springer Science and Business Media LLC; 2021; 10.1007/s12282-021-01283-4
• Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women Cite
  Evans DG, Howell SJ, Gandhi A, van Veen EM, Woodward ER, Harvey J, et al. Breast cancer incidence and early diagnosis in a family history risk and prevention clinic: 33-year experience in 14,311 women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06333-1
• Risk of Late-Onset Breast Cancer in Genetically Predisposed Women Cite
  Boddicker NJ, Hu C, Weitzel JN, Kraft P, Nathanson KL, Goldgar DE, et al. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021;:JCO.21.00531 10.1200/jco.21.00531
• Rate of breast biopsy referrals in BRCA mutation carriers: a retrospective comparative study and matched analysis Cite
  Pomerantz A, Tsoref D, Grubstein A, Wadhawker S, Rapson Y, Gadiel I, et al. Rate of breast biopsy referrals in BRCA mutation carriers: a retrospective comparative study and matched analysis. Research Square Platform LLC; 2021; 10.21203/rs.3.rs-670565/v1
• BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored Cite
  Crocetto F, Barone B, Caputo VF, Fontana M, de Cobelli O, Ferro M. BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored. Diagnostics. MDPI AG; 2021; 11:908 10.3390/diagnostics11050908
• High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer Cite
  Satyananda V, Oshi M, Endo I, Takabe K. High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2021; 10.1245/s10434-021-10063-5
• Heredity and Male Breast Cancer: A Series of 72 Men with Breast Cancer Cite
  Rodríguez-Fernández V, Cameselle-Cortizo L, García-Mallo A, Ortiz Elena M, Castro-Parga GJD, Figueiredo-Alonso E, et al. Heredity and Male Breast Cancer: A Series of 72 Men with Breast Cancer. International Journal of Medical Science and Health Research. International Journal of Medical Science and Health Research; 2021; 05:155-166 10.51505/ijmshr.2021.5213
• Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy Cite
  Michaelson-Cohen R, Gabizon–Peretz S, Armon S, Srebnik-Moshe N, Mor P, Tomer A, et al. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy. European Journal of Cancer. Elsevier BV; 2021; 148:95-102 10.1016/j.ejca.2021.02.007
• Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study Cite
  de Jonge MM, de Kroon CD, Jenner DJ, Oosting J, de Hullu JA, Mourits MJE, et al. Endometrial Cancer Risk in Women with Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2021; 10.1093/jnci/djab036
• Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations Cite
  Iyengar NM, Zhou XK, Mendieta H, El-Hely O, Giri DD, Winston L, et al. Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00226-8
• Survival from breast cancer in women with a BRCA2 mutation by treatment Cite
  Evans DG, Phillips K, Milne RL, Fruscio R, Cybulski C, Gronwald J, et al. Survival from breast cancer in women with a BRCA2 mutation by treatment. British Journal of Cancer. Springer Science and Business Media LLC; 2021; 10.1038/s41416-020-01164-1
• Post‐mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high‐risk breast cancer patients Cite
  Kanana N, Ben David MA, Nissan N, Yagil Y, Shalmon A, Halshtok O, et al. Post‐mastectomy surveillance of BRCA1/BRCA2 mutation carriers: Outcomes from a specialized clinic for high‐risk breast cancer patients. The Breast Journal. Wiley; 2021; 10.1111/tbj.14190
• Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants Cite
  Lambertini M, Ceppi M, Hamy A, Caron O, Poorvu PD, Carrasco E, et al. Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00224-w
• Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers Cite
  Stjepanovic N, Lubinski J, Moller P, Randall Armel S, Foulkes WD, Tung N, et al. Breast cancer risk after age 60 among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-020-06072-9
• BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients Cite
  Incorvaia L, Fanale D, Bono M, Calò V, Fiorino A, Brando C, et al. BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients. Therapeutic Advances in Medical Oncology. SAGE Publications; 2020; 12:175883592097532 10.1177/1758835920975326
• Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status Cite
  Olafsdottir EJ, Borg A, Jensen M, Gerdes A, Johansson ALV, Barkardottir RB, et al. Breast cancer survival in Nordic BRCA2 mutation carriers—unconventional association with oestrogen receptor status. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 123:1608-1615 10.1038/s41416-020-01056-4
• Trends in Positive BRCA Test Results Among Older Women in the United States, 2008-2018 Cite
  Guo F, Scholl M, Fuchs EL, Wong R, Kuo Y, Berenson AB. Trends in Positive BRCA Test Results Among Older Women in the United States, 2008-2018. JAMA Network Open. American Medical Association (AMA); 2020; 3:e2024358 10.1001/jamanetworkopen.2020.24358
• Time for BRCA Testing Among Women 65 Years or Older in the United States Cite
  Burton RC. Time for BRCA Testing Among Women 65 Years or Older in the United States. JAMA Network Open. American Medical Association (AMA); 2020; 3:e2024921 10.1001/jamanetworkopen.2020.24921
• Consumption of reused vegetable oil intensifies BRCA1 mutations Cite
  Rajendran P, Alzahrani AM, Rengarajan T, Veeraraghavan VP, Krishna Mohan S. Consumption of reused vegetable oil intensifies BRCA1 mutations. Critical Reviews in Food Science and Nutrition. Informa UK Limited; 2020;:1-8 10.1080/10408398.2020.1837725
• Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers Cite
  Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, et al. Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers. The American Surgeon. SAGE Publications; 2020; 86:1243-1247 10.1177/0003134820964208
• Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer Cite
  Lovejoy LA, Rummel SK, Turner CE, Shriver CD, Ellsworth RE. Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer. Familial Cancer. Springer Science and Business Media LLC; 2020; 10.1007/s10689-020-00213-1
• Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer Cite
  Sim EJ, Ko K, Ahn C, Park SM, Surh Y, An S, et al. Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 184:615-626 10.1007/s10549-020-05875-0
• 253P Preliminary report on survival outcomes of BRCA mutation carriers with triple-negative breast cancer Cite
  Aranda-Gutierrez A, Ferrigno A, Weitzel J, Moncada-Madrazo M, Gomez-Picos A, Castillo-Orozco A, et al. 253P Preliminary report on survival outcomes of BRCA mutation carriers with triple-negative breast cancer. Annals of Oncology. Elsevier BV; 2020; 31:S341 10.1016/j.annonc.2020.08.062
• Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling Cite
  Calip GS, Kidd J, Bernhisel R, Cox HC, Saam J, Rauscher GH, et al. Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2020; 10.1007/s10549-020-05922-w
• Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer Cite
  Guney Eskiler G, Sahin E, Deveci Ozkan A, Cilingir Kaya OT, Kaleli S. Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer. Nutrition and Cancer. Informa UK Limited; 2019; 72:1057-1066 10.1080/01635581.2019.1670216
• Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis Cite
  Metcalfe KA, Price MA, Mansfield C, Hallett DC, Lindeman GJ, Fairchild A, et al. Predictors of long-term cancer-related distress among female BRCA1 and BRCA2 mutation carriers without a cancer diagnosis: an international analysis. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 123:268-274 10.1038/s41416-020-0861-3
• Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations Cite
  Lambertini M, Ameye L, Hamy A, Zingarello A, Poorvu PD, Carrasco E, et al. Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:3012-3023 10.1200/jco.19.02399
• Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer Cite
  Collins JM, Isaacs C. Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer. The Breast Journal. Wiley; 2020; 26:1520-1527 10.1111/tbj.13970
• Special bioactive compounds and functional foods may exhibit neuroprotective effects in patients with dementia (Review) Cite
  Murakami M, Ikeda Y, Nakagawa Y, Tsuji A, Kitagishi Y, Matsuda S. Special bioactive compounds and functional foods may exhibit neuroprotective effects in patients with dementia (Review). Biomedical Reports. Spandidos Publications; 2020; 10.3892/br.2020.1310
• Abstract B105: The impact of ancestry on mutational and immune signatures in triple-negative breast cancers Cite
  Hughley RW, Yates C, Polak P. Abstract B105: The impact of ancestry on mutational and immune signatures in triple-negative breast cancers. Poster Presentations - Proffered Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7755.disp19-b105
• Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline Cite
  McGuire KP, Mamounas EP. Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2020; 27:1721-1723 10.1245/s10434-020-08396-8
• Abstract C052: Premenopausal oophorectomy and survival among women with breast cancer: Evidence of effect measure modification by family history status Cite
  Roberson ML, Robinson WR, Nichols HB, Olshan AF, Troester MA. Abstract C052: Premenopausal oophorectomy and survival among women with breast cancer: Evidence of effect measure modification by family history status. Poster Presentations - Proffered Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7755.disp18-c052
• Healthcare disparities and the demand for expanding hereditary breast cancer screening guidelines in African Americans. Cite
  Ciuro JA, Ahsan S, Beyer A, Jackson N. Healthcare disparities and the demand for expanding hereditary breast cancer screening guidelines in African Americans.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:e13636-e13636 10.1200/jco.2020.38.15_suppl.e13636
• Genetic Testing May Help Reduce Breast Cancer Disparities for African American Women Cite
  McCarthy AM, Armstrong K. Genetic Testing May Help Reduce Breast Cancer Disparities for African American Women. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2020; 112:1179-1180 10.1093/jnci/djaa042
• Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients Cite
  Tedaldi G, Tebaldi M, Zampiga V, Cangini I, Pirini F, Ferracci E, et al. Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients. Diagnostics. MDPI AG; 2020; 10:269 10.3390/diagnostics10050269
• Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes Cite
  De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, et al. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Scientific Reports. Springer Science and Business Media LLC; 2020; 10 10.1038/s41598-020-63759-1
• Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction Cite
  Stjepanovic N, Villacampa G, Nead KT, Torres-Esquius S, Melis GG, Nathanson KL, et al. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. European Journal of Cancer. Elsevier BV; 2020; 132:53-60 10.1016/j.ejca.2020.03.009
• Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study Cite
  Rettenmaier MA, Micha JP, Bohart R, Epstein HD, King MM, Goldstein BH. Incidence and Risk Factors of Ovarian Cancer and Breast Cancer Following Prophylactic Surgery: A Retrospective Cohort Study. Journal of Gynecologic Surgery. Mary Ann Liebert Inc; 2020; 36:189-193 10.1089/gyn.2019.0135
• Germline BRCA Mutation Rates in Latina Women Presenting for Gynecologic Oncology Care Cite
  Hong L, Gonzalez R, Unternaehrer J, Ioffe Y. Germline BRCA Mutation Rates in Latina Women Presenting for Gynecologic Oncology Care. Gynecologic and Obstetric Investigation. S. Karger AG; 2020; 85:214-221 10.1159/000506108
• Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review Cite
  Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of oral contraceptives in BRCA mutation carriers and risk for ovarian and breast cancer: a systematic review. Archives of Gynecology and Obstetrics. Springer Science and Business Media LLC; 2020; 301:875-884 10.1007/s00404-020-05458-w
• Abstract P6-08-21: Prevalence of HER2 positivity in germlineBRCA 1/2-associated breast cancers (gBRCA1/2-BC) Cite
  Whitaker K, Obeid E, Goldstein L, Daly M. Abstract P6-08-21: Prevalence of HER2 positivity in germlineBRCA 1/2-associated breast cancers (gBRCA1/2-BC). Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p6-08-21
• Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients Cite
  Su L, Xu Y, Ouyang T, Li J, Wang T, Fan Z, et al. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers in a large cohort of unselected Chinese breast cancer patients. International Journal of Cancer. Wiley; 2020; 146:3335-3342 10.1002/ijc.32918
• BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer Cite
  Tazzite A, Jouhadi H, Benider A, Nadifi S. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer. Current Drug Targets. Bentham Science Publishers Ltd.; 2020; 21:962-973 10.2174/1389450121666200203162541
• Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines Cite
  Al‑Yousef N, Shinwari Z, Al‑Shahrani B, Al‑Showimi M, Al‑Moghrabi N. Curcumin induces re‑expression of BRCA1 and suppression of γ synuclein by modulating DNA promoter methylation in breast cancer cell lines. Oncology Reports. Spandidos Publications; 2020; 10.3892/or.2020.7473
• Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers Cite
  Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, Noguès C, et al. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research. Springer Science and Business Media LLC; 2020; 22 10.1186/s13058-020-1247-4
• Should Genetic Testing for Cancer Predisposition Be Standard-of-Care for Women with Invasive Breast Cancer? The Murtha Cancer Center Experience Cite
  Rummel SK, Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE. Should Genetic Testing for Cancer Predisposition Be Standard-of-Care for Women with Invasive Breast Cancer? The Murtha Cancer Center Experience. Cancers. MDPI AG; 2020; 12:234 10.3390/cancers12010234
• Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers Cite
  Song Y, Barry WT, Seah DS, Tung NM, Garber JE, Lin NU. Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers. Cancer. Wiley; 2019; 126:271-280 10.1002/cncr.32540
• Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG) Cite
  Pal T, Agnese D, Daly M, La Spada A, Litton J, Wick M, et al. Points to consider: is there evidence to support BRCA1/2 and other inherited breast cancer genetic testing for all breast cancer patients? A statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine. Springer Science and Business Media LLC; 2019; 22:681-685 10.1038/s41436-019-0712-x
• Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium Cite
  Li H, Terry MB, Antoniou AC, Phillips K, Kast K, Mooij TM, et al. Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2019; 29:368-378 10.1158/1055-9965.epi-19-0546
• Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk Cite
  Kehm RD, Genkinger JM, MacInnis RJ, John EM, Phillips K, Dite GS, et al. Recreational Physical Activity Is Associated with Reduced Breast Cancer Risk in Adult Women at High Risk for Breast Cancer: A Cohort Study of Women Selected for Familial and Genetic Risk. Cancer Research. American Association for Cancer Research (AACR); 2019; 80:116-125 10.1158/0008-5472.can-19-1847
• Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing Cite
  Scarpitta R, Zanna I, Aretini P, Gambino G, Scatena C, Mei B, et al. Germline investigation in male breast cancer of DNA repair genes by next-generation sequencing. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 178:557-564 10.1007/s10549-019-05429-z
• Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer Cite
  Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. JAMA. American Medical Association (AMA); 2019; 322:652 10.1001/jama.2019.10987
• Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population‐based study Cite
  Wang T, McCullough LE, White AJ, Bradshaw PT, Xu X, Cho YH, et al. Prediagnosis aspirin use, DNA methylation, and mortality after breast cancer: A population‐based study. Cancer. Wiley; 2019; 125:3836-3844 10.1002/cncr.32364
• Hereditary Breast Cancer: Prophylactic Mastectomy, Breast Conservation, and Rates of Cancer Cite
  Walsh SM, Robson ME, Sacchini VS. Hereditary Breast Cancer: Prophylactic Mastectomy, Breast Conservation, and Rates of Cancer. Oncoplastic and Reconstructive Breast Surgery. Springer International Publishing; 2019;:33-42 10.1007/978-3-319-62927-8_4
• Assessment of breast cancer risk in BRCA carriers with ovarian cancer: Evaluation of data from longitudinal observation. Cite
  Safra T, Waissengrin B, Gerber D, Bernstein Molho R, Amit A, Salman L, et al. Assessment of breast cancer risk in BRCA carriers with ovarian cancer: Evaluation of data from longitudinal observation.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2019; 37:e13062-e13062 10.1200/jco.2019.37.15_suppl.e13062
• Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms Cite
  Bernstein-Molho R, Singer A, Laitman Y, Netzer I, Zalmanoviz S, Friedman E. Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 176:165-170 10.1007/s10549-019-05228-6
• The Effect of Green and Black Tea Polyphenols on BRCA2 Deficient Chinese Hamster Cells by Synthetic Lethality through PARP Inhibition Cite
  Alqahtani S, Welton K, Gius J, Elmegerhi S, Kato T. The Effect of Green and Black Tea Polyphenols on BRCA2 Deficient Chinese Hamster Cells by Synthetic Lethality through PARP Inhibition. International Journal of Molecular Sciences. MDPI AG; 2019; 20:1274 10.3390/ijms20061274
• Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers Cite
  Kotsopoulos J, Lubinski J, Lynch HT, Tung N, Armel S, Senter L, et al. Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:443-449 10.1007/s10549-019-05162-7
• Abstract P1-10-01: Defining the spectrum of germline variants among African American patients with triple negative breast cancer Cite
  Pederson H, Heald B, Budd G, Bernhisel R, Cummings S, Saam J, et al. Abstract P1-10-01: Defining the spectrum of germline variants among African American patients with triple negative breast cancer. Poster Session Abstracts. American Association for Cancer Research; 2019; 10.1158/1538-7445.sabcs18-p1-10-01
• 10-year performance of four models of breast cancer risk: a validation study Cite
  Terry MB, Liao Y, Whittemore AS, Leoce N, Buchsbaum R, Zeinomar N, et al. 10-year performance of four models of breast cancer risk: a validation study. The Lancet Oncology. Elsevier BV; 2019; 20:504-517 10.1016/s1470-2045(18)30902-1
• Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center Cite
  Frey MK, Kopparam RV, Ni Zhou Z, Fields JC, Buskwofie A, Carlson AD, et al. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center. Cancer. Wiley; 2018; 125:690-697 10.1002/cncr.31856
• BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients Cite
  Friedlaender A, Vuilleumier A, Viassolo V, Ayme A, De Talhouet S, Combes J, et al. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 174:775-783 10.1007/s10549-018-05127-2
• Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins Cite
  Khodabandehlou N, Mostafaei S, Etemadi A, Ghasemi A, Payandeh M, Hadifar S, et al. Human papilloma virus and breast cancer: the role of inflammation and viral expressed proteins. BMC Cancer. Springer Science and Business Media LLC; 2019; 19 10.1186/s12885-019-5286-0
• The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans Cite
  Kim H, Choi DH, Park W, Im Y, Ahn JS, Park YH, et al. The association between non-breast and ovary cancers and BRCA mutation in first- and second-degree relatives of high-risk breast cancer patients: a large-scale study of Koreans. Hereditary Cancer in Clinical Practice. Springer Science and Business Media LLC; 2019; 17 10.1186/s13053-018-0103-3
• Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer Cite
  Evron E, Ben-David A, Goldberg H, Fried G, Kaufman B, Catane R, et al. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer. Annals of Oncology. Elsevier BV; 2019; 30:412-417 10.1093/annonc/mdy515
• Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study Cite
  Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, et al. Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2018; 111:350-364 10.1093/jnci/djy132
• Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation Cite
  Baek HJ, Kim SE, Choi EK, Kim JK, Shin DH, Park EJ, et al. Inhibition of Estrogen Signaling Reduces the Incidence of BRCA1-associated Mammary Tumor Formation. International Journal of Biological Sciences. Ivyspring International Publisher; 2018; 14:1755-1768 10.7150/ijbs.28142
• A Dietary Intervention to Lower Serum Levels of IGF-I in BRCA Mutation Carriers Cite
  Pasanisi P, Bruno E, Venturelli E, Morelli D, Oliverio A, Baldassari I, et al. A Dietary Intervention to Lower Serum Levels of IGF-I in BRCA Mutation Carriers. Cancers. MDPI AG; 2018; 10:309 10.3390/cancers10090309
• Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers Cite
  Guindalini RSC, Zheng Y, Abe H, Whitaker K, Yoshimatsu TF, Walsh T, et al. Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers. Clinical Cancer Research. American Association for Cancer Research (AACR); 2018; 25:1786-1794 10.1158/1078-0432.ccr-18-0200
• Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis Cite
  Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, et al. Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis. Frontiers in Pharmacology. Frontiers Media SA; 2018; 9 10.3389/fphar.2018.00909
• The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations Cite
  Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, et al. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 172:151-157 10.1007/s10549-018-4887-7
• “I Am Uncertain About What My Uncertainty Even Is”: Men’s Uncertainty and Information Management of Their BRCA-Related Cancer Risks Cite
  Rauscher EA, Dean M, Campbell-Salome GM. “I Am Uncertain About What My Uncertainty Even Is”: Men’s Uncertainty and Information Management of Their BRCA-Related Cancer Risks. Journal of Genetic Counseling. Wiley; 2018; 27:1417-1427 10.1007/s10897-018-0276-y
• Abstract 248: Association of vitamin D related polymorphisms with hereditary breast cancer in 431 patients wild type forBRCA1andBRCA2mutations Cite
  Aristarco V, Serrano D, Barile M, Bondavalli D, Calvello M, Macis D, et al. Abstract 248: Association of vitamin D related polymorphisms with hereditary breast cancer in 431 patients wild type forBRCA1andBRCA2mutations. Epidemiology. American Association for Cancer Research; 2018; 10.1158/1538-7445.am2018-248
• Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer (EBC). Cite
  Evron E, Ben David MA, Goldberg H, Fried G, Kaufman B, Catane R, et al. Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer (EBC).. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:514-514 10.1200/jco.2018.36.15_suppl.514
• BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer Cite
  Zavitsanos PJ, Wazer DE, Hepel JT, Wang Y, Singh K, Leonard KL. BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer. American Journal of Clinical Oncology. Ovid Technologies (Wolters Kluwer Health); 2018; 41:1252-1256 10.1097/coc.0000000000000466
• What if I keep my breasts? Extended follow-up of unaffected BRCA mutation carriers diagnosed with breast cancer (BC) in the Toronto magnetic resonance imaging (MRI) screening study. Cite
  Warner E, Zhu S, Hill K, Causer P, Jong RA, Yaffe M, et al. What if I keep my breasts? Extended follow-up of unaffected BRCA mutation carriers diagnosed with breast cancer (BC) in the Toronto magnetic resonance imaging (MRI) screening study.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:1523-1523 10.1200/jco.2018.36.15_suppl.1523
• Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation Cite
  Kotsopoulos J, Gronwald J, Karlan B, Rosen B, Huzarski T, Moller P, et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology. Elsevier BV; 2018; 150:85-91 10.1016/j.ygyno.2018.05.011
• Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers Cite
  Kotsopoulos J, Gronwald J, Lynch HT, Eisen A, Neuhausen SL, Tung N, et al. Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 171:421-426 10.1007/s10549-018-4822-y
• Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers Cite
  Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, et al. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. JAMA Oncology. American Medical Association (AMA); 2018; 4:1059 10.1001/jamaoncol.2018.0211
• Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers Cite
  Rizzolo P, Silvestri V, Valentini V, Zelli V, Zanna I, Masala G, et al. Gene-specific methylation profiles in BRCA-mutation positive and BRCA-mutation negative male breast cancers. Oncotarget. Impact Journals, LLC; 2018; 9:19783-19792 10.18632/oncotarget.24856
• Risk-reducing mastectomy for the prevention of primary breast cancer Cite
  Carbine NE, Lostumbo L, Wallace J, Ko H. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database of Systematic Reviews. Wiley; 2018; 10.1002/14651858.cd002748.pub4
• Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women’s Environmental Cancer and Radiation Epidemiology Study Cite
  Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, et al. Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women’s Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:1513-1520 10.1200/jco.2017.77.3424
• Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history Cite
  Engel C, Rhiem K, Hahnen E, Loibl S, Weber KE, Seiler S, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4029-y
• BRCA1 risk-reducing surgery appears to reduce risk of developing breast cancer Cite
  Irwin G, Hinds G, McFaul L, Morrison P, Harley I, McIntosh S. BRCA1 risk-reducing surgery appears to reduce risk of developing breast cancer. European Journal of Surgical Oncology. Elsevier BV; 2018; 44:S4 10.1016/j.ejso.2018.01.236
• Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers Cite
  Lammert J, Lubinski J, Gronwald J, Huzarski T, Armel S, Eisen A, et al. Physical activity during adolescence and young adulthood and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 169:561-571 10.1007/s10549-018-4694-1
• Male BRCA mutation carriers: clinical characteristics and cancer spectrum Cite
  Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer. Springer Science and Business Media LLC; 2018; 18 10.1186/s12885-018-4098-y
• The frequency of missed breast cancers in women participating in a high-risk MRI screening program Cite
  Vreemann S, Gubern-Merida A, Lardenoije S, Bult P, Karssemeijer N, Pinker K, et al. The frequency of missed breast cancers in women participating in a high-risk MRI screening program. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 169:323-331 10.1007/s10549-018-4688-z
• Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer Cite
  Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, et al. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer. Clinical Breast Cancer. Elsevier BV; 2018; 18:e1229-e1235 10.1016/j.clbc.2017.12.014
• BRCAmutations in women with inflammatory breast cancer Cite
  Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, et al. BRCAmutations in women with inflammatory breast cancer. Cancer. Wiley; 2017; 124:466-474 10.1002/cncr.31069
• The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers Cite
  Ko K, Kim SJ, Huzarski T, Gronwald J, Lubinski J, Lynch HT, et al. The association between smoking and cancer incidence in BRCA1 and BRCA2 mutation carriers. International Journal of Cancer. Wiley; 2018; 142:2263-2272 10.1002/ijc.31257
• Fertility preservation in BRCA-mutated women: when and how? Cite
  Grynberg M, Raad J, Comtet M, Vinolas C, Cédrin-Durnerin I, Sonigo C. Fertility preservation in BRCA-mutated women: when and how?. Future Oncology. Future Medicine Ltd; 2018; 14:483-490 10.2217/fon-2017-0415
• Abstract P4-02-10: Breast cancer surveillance in high-risk women with dynamic contrast-enhanced magnetic resonance imaging every 6 months: Results from a single institution study Cite
  Whitaker K, Guindalini R, Abe H, Sheeth D, Huo D, Hong S, et al. Abstract P4-02-10: Breast cancer surveillance in high-risk women with dynamic contrast-enhanced magnetic resonance imaging every 6 months: Results from a single institution study. Poster Session Abstracts. American Association for Cancer Research; 2018; 10.1158/1538-7445.sabcs17-p4-02-10
• Predictors of survival for breast cancer patients with a BRCA1 mutation Cite
  Narod SA, Huzarski T, Gronwald J, Byrski T, Marczyk E, Cybulski C, et al. Predictors of survival for breast cancer patients with a BRCA1 mutation. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 168:513-521 10.1007/s10549-017-4605-x
• Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women Cite
  Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, et al. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. JAMA Oncology. American Medical Association (AMA); 2017; 3:1647 10.1001/jamaoncol.2017.1996
• The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy Cite
  Giannakeas V, Narod SA. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:263-267 10.1007/s10549-017-4476-1
• BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers Cite
  Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, et al. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nature Communications. Springer Science and Business Media LLC; 2017; 8 10.1038/s41467-017-00388-9
• Ovarian Aging in Women With BRCA Germline Mutations Cite
  Lin W, Titus S, Moy F, Ginsburg ES, Oktay K. Ovarian Aging in Women With BRCA Germline Mutations. The Journal of Clinical Endocrinology & Metabolism. The Endocrine Society; 2017; 102:3839-3847 10.1210/jc.2017-00765
• Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations Cite
  Ha SM, Chae EY, Cha JH, Kim HH, Shin HJ, Choi WJ. Association of BRCA Mutation Types, Imaging Features, and Pathologic Findings in Patients With Breast Cancer With BRCA1 and BRCA2 Mutations. American Journal of Roentgenology. American Roentgen Ray Society; 2017; 209:920-928 10.2214/ajr.16.16957
• Was Angelina Jolie Right? Optimizing Cancer Prevention Strategies Among BRCA Mutation Carriers Cite
  Nohdurft E, Long E, Spinler S. Was Angelina Jolie Right? Optimizing Cancer Prevention Strategies Among BRCA Mutation Carriers. Decision Analysis. Institute for Operations Research and the Management Sciences (INFORMS); 2017; 14:139-169 10.1287/deca.2017.0352
• Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients Cite
  Sun J, Meng H, Yao L, Lv M, Bai J, Zhang J, et al. Germline Mutations in Cancer Susceptibility Genes in a Large Series of Unselected Breast Cancer Patients. Clinical Cancer Research. American Association for Cancer Research (AACR); 2017; 23:6113-6119 10.1158/1078-0432.ccr-16-3227
• Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population Cite
  Reiner AS, Lynch CF, Sisti JS, John EM, Brooks JD, Bernstein L, et al. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Research. Springer Science and Business Media LLC; 2017; 19 10.1186/s13058-017-0874-x
• Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes Cite
  Parkes A, Arun BK, Litton JK. Systemic Treatment Strategies for Patients with Hereditary Breast Cancer Syndromes. The Oncologist. Wiley; 2017; 22:655-666 10.1634/theoncologist.2016-0430
• Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography Cite
  van Zelst JCM, Mus RDM, Woldringh G, Rutten MJCM, Bult P, Vreemann S, et al. Surveillance of Women with the BRCA1 or BRCA2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography. Radiology. Radiological Society of North America (RSNA); 2017; 285:376-388 10.1148/radiol.2017161218
• Clinical outcomes of female breast cancer according to BRCA mutation status Cite
  Cronin-Fenton DP, Kjærsgaard A, Nørgaard M, Pedersen IS, Thomassen M, Kaye JA, et al. Clinical outcomes of female breast cancer according to BRCA mutation status. Cancer Epidemiology. Elsevier BV; 2017; 49:128-137 10.1016/j.canep.2017.05.016
• Effects of lifestyle and diet as modifiers of risk of breast cancer (BC) in BRCA1 and BRCA2 carriers. Cite
  Pollan M, Torres A, Ramon Y Cajal T, Llort G, Castello A, Fisas D, et al. Effects of lifestyle and diet as modifiers of risk of breast cancer (BC) in BRCA1 and BRCA2 carriers.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:1505-1505 10.1200/jco.2017.35.15_suppl.1505
• Aldehydes Pose a Threat to BRCA2 Mutation Carriers Cite
  Parmar K, D’Andrea AD. Aldehydes Pose a Threat to BRCA2 Mutation Carriers. Cell. Elsevier BV; 2017; 169:979-981 10.1016/j.cell.2017.05.021
• Family history of breast cancer in non-BRCA male breast cancer: A case-control study. Cite
  Calip GS, Exten KR, Rauscher GH, Brown K, Bernhisel R, Kidd J, et al. Family history of breast cancer in non-BRCA male breast cancer: A case-control study.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:e13032-e13032 10.1200/jco.2017.35.15_suppl.e13032
• Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes Cite
  Frey MK, Sandler G, Sobolev R, Kim SH, Chambers R, Bassett RY, et al. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes. Gynecologic Oncology. Elsevier BV; 2017; 146:123-128 10.1016/j.ygyno.2017.04.009
• Lymph node status as a prognostic factor in BRCA-positive breast cancer Cite
  Lee J, Park HY, Jung JH, Kim WW, Chae YS, Lee SJ, et al. Lymph node status as a prognostic factor in BRCA-positive breast cancer. Journal of Surgical Research. Elsevier BV; 2017; 215:125-131 10.1016/j.jss.2017.03.065
• Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women Cite
  Schmidt MK, van den Broek AJ, Tollenaar RAEM, Smit VTHBM, Westenend PJ, Brinkhuis M, et al. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2017; 109 10.1093/jnci/djw329
• Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers Cite
  Krammer J, Pinker-Domenig K, Robson ME, Gönen M, Bernard-Davila B, Morris EA, et al. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 163:565-571 10.1007/s10549-017-4198-4
• Racial disparities inBRCAtesting and cancer risk management across a population-based sample of young breast cancer survivors Cite
  Cragun D, Weidner A, Lewis C, Bonner D, Kim J, Vadaparampil ST, et al. Racial disparities inBRCAtesting and cancer risk management across a population-based sample of young breast cancer survivors. Cancer. Wiley; 2017; 123:2497-2505 10.1002/cncr.30621
• Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function Cite
  Mgbemena VE, Signer RA, Wijayatunge R, Laxson T, Morrison SJ, Ross TS. Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function. Cell Reports. Elsevier BV; 2017; 18:947-960 10.1016/j.celrep.2016.12.075
• Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance Cite
  Afghahi A, Timms KM, Vinayak S, Jensen KC, Kurian AW, Carlson RW, et al. Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Clinical Cancer Research. American Association for Cancer Research (AACR); 2017; 23:3365-3370 10.1158/1078-0432.ccr-16-2174
• Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results Cite
  Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, et al. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 161:575-586 10.1007/s10549-016-4085-4
• BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer Cite
  Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y, et al. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0167016 10.1371/journal.pone.0167016
• BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy Cite
  Tanino H, Kosaka Y, Nishimiya H, Tanaka Y, Minatani N, Kikuchi M, et al. BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0165721 10.1371/journal.pone.0165721
• Tumor characteristics and prognosis in familial breast cancer Cite
  Arpino G, Pensabene M, Condello C, Ruocco R, Cerillo I, Lauria R, et al. Tumor characteristics and prognosis in familial breast cancer. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2962-1
• Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients Cite
  Jung J, Kang E, Gwak J, Seo A, Park S, Lee A, et al. Association between basal-like phenotype and BRCA1/2 germline mutations in Korean breast cancer patients. Current Oncology. MDPI AG; 2016; 23:298 10.3747/co.23.3054
• Early onset breast cancer in Ashkenazi women carriers of founderBRCA1/2mutations: beyond 10 years of follow-up Cite
  Dagan E, Gershoni-Baruch R, Kurolap A, Fried G. Early onset breast cancer in Ashkenazi women carriers of founderBRCA1/2mutations: beyond 10 years of follow-up. European Journal of Cancer Care. Wiley; 2016; 26:e12594 10.1111/ecc.12594
• Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History Cite
  Bradbury AR, Patrick-Miller L, Schwartz LA, Egleston BL, Henry-Moss D, Domchek SM, et al. Psychosocial Adjustment and Perceived Risk Among Adolescent Girls From Families With BRCA1/2 or Breast Cancer History. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:3409-3416 10.1200/jco.2015.66.3450
• BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis Cite
  Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. Impact Journals, LLC; 2016; 7:70113-70127 10.18632/oncotarget.12158
• Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers Cite
  Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, et al. Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2016; 109 10.1093/jnci/djw177
• Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers Cite
  Lee Y, Lee S, Kim K, Jung K, Lee J, Kim Y. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. Journal of Gynecologic Oncology. Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy; 2017; 28 10.3802/jgo.2017.28.e3
• High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients Cite
  Rashid MU, Muhammad N, Bajwa S, Faisal S, Tahseen M, Bermejo JL, et al. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2698-y
• Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas Cite
  Pinto P, Peixoto A, Santos C, Rocha P, Pinto C, Pinheiro M, et al. Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0161438 10.1371/journal.pone.0161438
• Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers Cite
  Jonasson JG, Stefansson OA, Johannsson OT, Sigurdsson H, Agnarsson BA, Olafsdottir GH, et al. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 115:776-783 10.1038/bjc.2016.249
• Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon? Cite
  Agranat S, Baris H, Kedar I, Shochat M, Rizel S, Perry S, et al. Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon?. The Breast Journal. Wiley; 2016; 22:662-666 10.1111/tbj.12653
• Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study Cite
  Kim SJ, Zuchniak A, Sohn K, Lubinski J, Demsky R, Eisen A, et al. Plasma folate, vitamin B-6, and vitamin B-12 and breast cancer risk in BRCA1- and BRCA2-mutation carriers: a prospective study. The American Journal of Clinical Nutrition. Oxford University Press (OUP); 2016; 104:671-677 10.3945/ajcn.116.133470
• Abstract 1786: One in four Hispanic women with early onset breast cancer carry BRCA1, BRCA2, or PALB2 mutations: Results from a population-based study in South America Cite
  Tuazon AM, Bohorquez M, Ramirez C, Lott P, Estrada A, Criollo A, et al. Abstract 1786: One in four Hispanic women with early onset breast cancer carry BRCA1, BRCA2, or PALB2 mutations: Results from a population-based study in South America. Epidemiology. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-1786
• Abstract 2544: Association between flame-broiled fish consumption and breast cancer: A case-control study in women with high familial risk Cite
  Kaushiva A, May B, Armstrong D, Axilbund J, Visvanathan K. Abstract 2544: Association between flame-broiled fish consumption and breast cancer: A case-control study in women with high familial risk. Epidemiology. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-2544
• Cancer Incidence in First‐ and Second‐Degree Relatives of BRCA1 and BRCA2 Mutation Carriers Cite
  Streff H, Profato J, Ye Y, Nebgen D, Peterson SK, Singletary C, et al. Cancer Incidence in First‐ and Second‐Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. The Oncologist. Wiley; 2016; 21:869-874 10.1634/theoncologist.2015-0354
• Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis Cite
  Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V, et al. Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. BMC Cancer. Springer Science and Business Media LLC; 2016; 16 10.1186/s12885-016-2414-y
• Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations Cite
  Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncology. American Medical Association (AMA); 2016; 2:1434 10.1001/jamaoncol.2016.1820
• Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors. Cite
  Pal T, Cragun D, Lewis C, Bonner D, Camperlengo LP, Vadaparampil ST. Disparities in cancer risk management among BRCA carriers across a diverse sample of young black, Hispanic, and non-Hispanic white breast cancer survivors.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:LBA1504-LBA1504 10.1200/jco.2016.34.15_suppl.lba1504
• Anti-Müllerian hormone serum concentrations of women with germlineBRCA1orBRCA2mutations Cite
  Phillips K, Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, et al. Anti-Müllerian hormone serum concentrations of women with germlineBRCA1orBRCA2mutations. Human Reproduction. Oxford University Press (OUP); 2016; 31:1126-1132 10.1093/humrep/dew044
• The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study Cite
  Iqbal J, Nussenzweig A, Lubinski J, Byrski T, Eisen A, Bordeleau L, et al. The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study. British Journal of Cancer. Springer Science and Business Media LLC; 2016; 114:1160-1164 10.1038/bjc.2016.58
• Abstract P6-10-17: Rates of prophylactic surgeries among BRCA 1 or 2 mutation carriers: A single institution experience Cite
  Raphael J, Hewitt P, Graham T, Ott K, Mancuso T, Lorentz J, et al. Abstract P6-10-17: Rates of prophylactic surgeries among BRCA 1 or 2 mutation carriers: A single institution experience. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p6-10-17
• Abstract P2-09-03: Breast cancer prevention: Is it time for population-based mutation screening of high risk genes? Cite
  Campbell I, Trainer A, Devereux L, Young M, Mitchell G, Rowley S, et al. Abstract P2-09-03: Breast cancer prevention: Is it time for population-based mutation screening of high risk genes?. Poster Session Abstracts. American Association for Cancer Research; 2016; 10.1158/1538-7445.sabcs15-p2-09-03
• Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens Cite
  Evans DG, Lalloo F, Howell S, Verhoef S, Woodward ER, Howell A. Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:597-601 10.1007/s10549-016-3697-z
• Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 Cite
  Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0671-y
• Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study Cite
  Kotsopoulos J, Huzarski T, Gronwald J, Moller P, Lynch HT, Neuhausen SL, et al. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 155:365-373 10.1007/s10549-016-3685-3
• Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation Cite
  Gronwald J, Glass K, Rosen B, Karlan B, Tung N, Neuhausen SL, et al. Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Fertility and Sterility. Elsevier BV; 2016; 105:781-785 10.1016/j.fertnstert.2015.11.034
• Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers Cite
  Rieder V, Salama M, Glöckner L, Muhr D, Berger A, Tea M, et al. Effect of lifestyle and reproductive factors on the onset of breast cancer in female BRCA 1 and 2 mutation carriers. Molecular Genetics & Genomic Medicine. Wiley; 2015; 4:172-177 10.1002/mgg3.191
• Breast cancer 1 (BRCA1)-deficient embryos develop normally but are more susceptible to ethanol-initiated DNA damage and embryopathies Cite
  Shapiro AM, Miller-Pinsler L, Wells PG. Breast cancer 1 (BRCA1)-deficient embryos develop normally but are more susceptible to ethanol-initiated DNA damage and embryopathies. Redox Biology. Elsevier BV; 2016; 7:30-38 10.1016/j.redox.2015.11.005
• BRCA1 Mutation: A Predictive Marker for Radiation Therapy? Cite
  Kan C, Zhang J. BRCA1 Mutation: A Predictive Marker for Radiation Therapy?. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2015; 93:281-293 10.1016/j.ijrobp.2015.05.037
• BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk Cite
  Kwiatkowski F, Arbre M, Bidet Y, Laquet C, Uhrhammer N, Bignon Y. BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0127363 10.1371/journal.pone.0127363
• Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage Cite
  Palomaki GE. Screening for breast cancer by molecular testing for three founder mutations in the BRCA1 and BRCA2 genes among women of Ashkenazi Jewish heritage. Journal of Medical Screening. SAGE Publications; 2015; 22:109-111 10.1177/0969141315579701
• Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis Cite
  van den Broek AJ, Schmidt MK, van ‘t Veer LJ, Tollenaar RAEM, van Leeuwen FE. Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis. PLOS ONE. Public Library of Science (PLoS); 2015; 10:e0120189 10.1371/journal.pone.0120189
• Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience Cite
  Asleh-Aburaya K, Fried G. Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience. SpringerPlus. Springer Science and Business Media LLC; 2015; 4 10.1186/s40064-015-0900-3
• Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer Cite
  Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, et al. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. Annals of Oncology. Elsevier BV; 2015; 26:523-528 10.1093/annonc/mdu559
• Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction Cite
  Heemskerk-Gerritsen BAM, Seynaeve C, van Asperen CJ, Ausems MGEM, Collée JM, van Doorn HC, et al. Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 107 10.1093/jnci/djv033
• Intensified Surveillance for Early Detection of Breast Cancer in High-Risk Patients Cite
  Bick U. Intensified Surveillance for Early Detection of Breast Cancer in High-Risk Patients. Breast Care. S. Karger AG; 2015; 10:13-20 10.1159/000375390
• Evolution of Genetic Testing for Inherited Susceptibility to Breast Cancer Cite
  Domchek SM. Evolution of Genetic Testing for Inherited Susceptibility to Breast Cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015; 33:295-296 10.1200/jco.2014.59.3178
• Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less Cite
  Bayraktar S, Amendola L, Gutierrez-Barrera AM, Hashmi SS, Amos C, Gambello M, et al. Clinicopathologic characteristics of breast cancer in BRCA-carriers and non-carriers in women 35 years of age or less. The Breast. Elsevier BV; 2014; 23:770-774 10.1016/j.breast.2014.08.010
• Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis Cite
  Friebel TM, Domchek SM, Rebbeck TR. Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2014; 106 10.1093/jnci/dju091
• Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis Cite
  Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. BMJ; 2014; 348:g226-g226 10.1136/bmj.g226
• Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status Cite
  Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N. Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 144:133-142 10.1007/s10549-014-2842-9
• Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers Cite
  Kotsopoulos J, Lubinski J, Moller P, Lynch HT, Singer CF, Eng C, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 143:579-586 10.1007/s10549-013-2823-4
• The Influence ofBRCA1/BRCA2Mutations on Toxicity Related to Chemotherapy and Radiotherapy in Early Breast Cancer Patients Cite
  Huszno J, Budryk M, Kolosza Z, Nowara E. The Influence ofBRCA1/BRCA2Mutations on Toxicity Related to Chemotherapy and Radiotherapy in Early Breast Cancer Patients. Oncology. S. Karger AG; 2013; 85:278-282 10.1159/000354834
• BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer Cite
  SAMBIASI D, LAMBO R, PILATO B, TOMMASI S, TROJANO G, KARDHASHI A, et al. BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer. Oncology Reports. Spandidos Publications; 2013; 31:365-369 10.3892/or.2013.2802
• Central European BRCA2 mutation carriers: Birth cohort status correlates with onset of breast cancer Cite
  Tea MM, Kroiss R, Muhr D, Fuerhauser-Rappaport C, Oefner P, Wagner TM, et al. Central European BRCA2 mutation carriers: Birth cohort status correlates with onset of breast cancer. Maturitas. Elsevier BV; 2014; 77:68-72 10.1016/j.maturitas.2013.09.012
• Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE Cite
  Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:812-822 10.1093/jnci/djt095
• Proven non-carriers in BRCA families have an earlier age of onset of breast cancer Cite
  Vos JR, de Bock GH, Teixeira N, van der Kolk DM, Jansen L, Mourits MJ, et al. Proven non-carriers in BRCA families have an earlier age of onset of breast cancer. European Journal of Cancer. Elsevier BV; 2013; 49:2101-2106 10.1016/j.ejca.2013.02.018
• BRCA1 loss activates cathepsin L–mediated degradation of 53BP1 in breast cancer cells Cite
  Grotsky DA, Gonzalez-Suarez I, Novell A, Neumann MA, Yaddanapudi SC, Croke M, et al. BRCA1 loss activates cathepsin L–mediated degradation of 53BP1 in breast cancer cells. Journal of Cell Biology. Rockefeller University Press; 2013; 200:187-202 10.1083/jcb.201204053
• Mutation Analysis of BRCA1, BRCA2, PALB2 and BRD7 in a Hospital-Based Series of German Patients with Triple-Negative Breast Cancer Cite
  Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F, et al. Mutation Analysis of BRCA1, BRCA2, PALB2 and BRD7 in a Hospital-Based Series of German Patients with Triple-Negative Breast Cancer. PLoS ONE. Public Library of Science (PLoS); 2012; 7:e47993 10.1371/journal.pone.0047993
• Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK) Cite
  Pijpe A, Andrieu N, Easton DF, Kesminiene A, Cardis E, Nogues C, et al. Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK). BMJ. BMJ; 2012; 345:e5660-e5660 10.1136/bmj.e5660
• Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis Cite
  Cibula D, Zikan M, Dusek L, Majek O. Oral contraceptives and risk of ovarian and breast cancers inBRCAmutation carriers: a meta-analysis. Expert Review of Anticancer Therapy. Informa UK Limited; 2011; 11:1197-1207 10.1586/era.11.38
• N’oubliez pas les trompes ! Étude morphologique et immunohistochimique des trompes à risque génétique (mutation BRCA) Cite
  Chêne G, Raoelfils I, Cayre A, Dauplat J, Bignon Y, Jaffeux P, et al. N’oubliez pas les trompes ! Étude morphologique et immunohistochimique des trompes à risque génétique (mutation BRCA). Gynécologie Obstétrique & Fertilité. Elsevier BV; 2012; 40:14-18 10.1016/j.gyobfe.2011.07.043
• Impact of X Chromosome Genes in Explaining the Excess Risk of Cancer in Males Cite
  Biggar RJ, Bergen AW, Poulsen GN. Impact of X Chromosome Genes in Explaining the Excess Risk of Cancer in Males. American Journal of Epidemiology. Oxford University Press (OUP); 2009; 170:65-71 10.1093/aje/kwp083
• P2-13-02: Parent of Origin of BRCA Mutation May Determine Age at Breast Cancer Diagnosis. Cite
  Shapira I, Budman D, Akerman M, Weiselberg L, Vinciguerra V, D'Olimpio J, et al. P2-13-02: Parent of Origin of BRCA Mutation May Determine Age at Breast Cancer Diagnosis.. Poster Session Abstracts. American Association for Cancer Research; 2011; 10.1158/0008-5472.sabcs11-p2-13-02
• Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers? Cite
  Bernholtz S, Laitman Y, Kaufman B, Shimon-Paluch S, Friedman E. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 132:669-673 10.1007/s10549-011-1886-3
• Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry Cite
  Kurian AW, Gong GD, John EM, Johnston DA, Felberg A, West DW, et al. Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: Findings From the Breast Cancer Family Registry. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:4505-4509 10.1200/jco.2010.34.4440
• High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients Cite
  Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos F, Burrill DR, et al. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. International Journal of Cancer. Wiley; 2012; 131:1114-1123 10.1002/ijc.27326
• Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers Cite
  Bernholtz S, Jakobson-Setton A, Korach J, Ben Baruch G, Laitman Y, Friedman E. Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2011; 131:981-985 10.1007/s10549-011-1807-5
• Earlier age of onset ofBRCAmutation-related cancers in subsequent generations Cite
  Litton JK, Ready K, Chen H, Gutierrez-Barrera A, Etzel CJ, Meric-Bernstam F, et al. Earlier age of onset ofBRCAmutation-related cancers in subsequent generations. Cancer. Wiley; 2011; 118:321-325 10.1002/cncr.26284
• Does maternal or paternal inheritance of BRCA mutation affect the age of cancer diagnosis? Cite
  Shapira I, Gralla RJ, Akerman M, Weiselberg LR, John VS, Raftopoulos H, et al. Does maternal or paternal inheritance of BRCA mutation affect the age of cancer diagnosis?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:1510-1510 10.1200/jco.2011.29.15_suppl.1510
• Patient and tumor characteristics associated with contralateral breast cancer in a nested population-based case-control study. Cite
  Junqueira MJ, Morrow M, Reiner AS, Malone K, Lynch C, Bernstein JL. Patient and tumor characteristics associated with contralateral breast cancer in a nested population-based case-control study.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:1014-1014 10.1200/jco.2011.29.15_suppl.1014
• Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers Cite
  Lee LJ, Alexander B, Schnitt SJ, Comander A, Gallagher B, Garber JE, et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer. Wiley; 2011; 117:3093-3100 10.1002/cncr.25911
• Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations Cite
  Dite GS, Whittemore AS, Knight JA, John EM, Milne RL, Andrulis IL, et al. Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations. British Journal of Cancer. Springer Science and Business Media LLC; 2010; 103:1103-1108 10.1038/sj.bjc.6605876
• Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk Cite
  Phipps AI, Buist DSM, Malone KE, Barlow WE, Porter PL, Kerlikowske K, et al. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 126:671-678 10.1007/s10549-010-1148-9
• Risk of breast cancer in male BRCA2 carriers Cite
  Evans DGR, Susnerwala I, Dawson J, Woodward E, Maher ER, Lalloo F. Risk of breast cancer in male BRCA2 carriers. Journal of Medical Genetics. BMJ; 2010; 47:710-711 10.1136/jmg.2009.075176
• Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer Cite
  Ellberg C, Olsson H. Breast cancer patients with lobular cancer more commonly have a father than a mother diagnosed with cancer. BMC Cancer. Springer Science and Business Media LLC; 2011; 11 10.1186/1471-2407-11-497
• Characterizing benign breast disease in women at high risk for breast cancer. Cite
  Israel SA, Nassar H, Gross AL, Jacobs LK, Armstrong DK, Visvanathan K. Characterizing benign breast disease in women at high risk for breast cancer.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1506-1506 10.1200/jco.2010.28.15_suppl.1506
• 500 Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival? Cite
  Heemskerk-Gerritsen B, Hooning M, Jager A, Tilanus-Linthorst M, Bartels C, van den Ouweland A, et al. 500 Is risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer beneficial with respect to distant disease free survival and overall survival?. European Journal of Cancer Supplements. Elsevier BV; 2010; 8:206 10.1016/s1359-6349(10)70521-8
• Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age Cite
  van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJE, de Vries J, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 124:643-651 10.1007/s10549-010-0805-3
• Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial Cite
  Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, König R, et al. Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1450-1457 10.1200/jco.2009.23.0839
• Screening for Founder Mutations in BRCA1 and BRCA2 in Unselected Jewish Women Cite
  Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, et al. Screening for Founder Mutations in BRCA1 and BRCA2 in Unselected Jewish Women. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:387-391 10.1200/jco.2009.25.0712
• Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening Cite
  Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L, et al. Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. Journal of Medical Genetics. BMJ; 2006; 44:10-15 10.1136/jmg.2006.043091
• Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2 Cite
  Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, et al. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 119:409-414 10.1007/s10549-009-0611-y
• Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers in the Netherlands. Cite
  Pijpe A, Manders P, van Leeuwen F, Rookus M. Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers in the Netherlands.. Poster Discussion Abstracts. American Association for Cancer Research; 2009; 10.1158/0008-5472.sabcs-505
• Breast and Ovarian Cancer in Relatives of Cancer Patients, with and without BRCA Mutations Cite
  Lee JS, John EM, McGuire V, Felberg A, Ostrow KL, DiCioccio RA, et al. Breast and Ovarian Cancer in Relatives of Cancer Patients, with and without BRCA Mutations. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2006; 15:359-363 10.1158/1055-9965.epi-05-0687
• Growth Hormone and Insulin-Like Growth Factor-I in the Transition from Normal Mammary Development to Preneoplastic Mammary Lesions Cite
  Kleinberg DL, Wood TL, Furth PA, Lee AV. Growth Hormone and Insulin-Like Growth Factor-I in the Transition from Normal Mammary Development to Preneoplastic Mammary Lesions. Endocrine Reviews. The Endocrine Society; 2008; 30:51-74 10.1210/er.2008-0022